Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaDeJ: De-escalation of primary chemoradiotherapy in HPV-associated oropharyngeal squamous cell carcinoma
2024-517832-23-00Phase 2Authorised
- Sponsor
- Východoslovenský onkologický ústav
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Východoslovenský onkologický ústav. Primary endpoint: Two-year locoregional control. Planned start Nov 2024; status: authorised.
02
Drugs
cisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on 2024-517832-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517832-23-00.